CHARGE syndrome is a rare genetic disorder characterized by a distinctive pattern of congenital anomalies and associated neurodevelopmental challenges. The name CHARGE is an acronym for the classic features: Coloboma, Heart defects, Atresia choanae, Growth retardation, Ear abnormalities, and Genital abnormalities. While primarily considered a neurodevelopmental disorder, recent research has revealed important connections to neurodegenerative processes through epigenetic dysregulation mechanisms.
CHARGE syndrome is a genetic disorder affecting multiple systems is a condition with relevance to the neurodegenerative disease landscape. This page covers its molecular basis, clinical features, genetic associations, and connections to broader neurodegeneration research. The syndrome has an estimated prevalence of approximately 1 in 8,500 to 1 in 15,000 live births, making it one of the rarer genetic syndromes involving the nervous system. [1]
CHARGE syndrome is primarily caused by heterozygous mutations in the CHD7 gene (Chromodomain Helicase DNA Binding Protein 7), which follows an autosomal dominant inheritance pattern. [2] Approximately two-thirds of individuals with CHARGE syndrome have a detectable pathogenic variant in CHD7. [3]
CHD7 is a key epigenetic regulator, and its dysfunction contributes to broader neurodegeneration pathways — see Epigenetic Dysregulation Pathway and Epigenetics in Neurodegeneration.
The hallmark features of CHARGE syndrome include: [4]
CHARGE syndrome involves significant neurodevelopmental manifestations that persist into adulthood: [5]
The neurodevelopmental features of CHARGE syndrome involve disruption of key brain regions and systems:
Emerging evidence suggests that individuals with CHARGE syndrome may have increased susceptibility to neurodegenerative processes later in life due to: [6]
CHD7 is a member of the chromodomain helicase DNA-binding (CHD) family of proteins that utilize ATP to remodel chromatin structure. [7] Key functions include:
Management of CHARGE syndrome requires a multidisciplinary approach: [8]
See Immunotherapy for Neurodegenerative Diseases for emerging therapeutic approaches.
Understanding CHD7 function provides insights into broader Epigenetic Therapies for Neurodegeneration. Chromatin remodelers represent potential therapeutic targets for: [9]
Research into CHARGE syndrome contributes to understanding Adult Neurogenesis in Neurodegenerative Disease and potential regeneration strategies.
National Institutes of Health, CHARGE Syndrome Epidemiology (2023). 2023. ↩︎
Vissers et al. Mutations in CHD7 cause CHARGE syndrome (2004). 2004. ↩︎
Bergman et al. CHD7 mutation spectrum in CHARGE syndrome (2011). 2011. ↩︎
CHARGE Syndrome Foundation, Clinical Features (2024). 2024. ↩︎
Hartshorne et al. Neurodevelopmental outcomes in CHARGE syndrome (2022). 2022. ↩︎
Srivastava et al. Epigenetic dysregulation and neurodegeneration in CHD7-related disorders (2024). 2024. ↩︎
Kadoch et al. CHD chromatin remodelers: Structure and function (2023). 2023. ↩︎
Legendre et al. Comprehensive management of CHARGE syndrome (2024). 2024. ↩︎
Fischer et al. Epigenetic therapies for neurodegenerative diseases (2024). 2024. ↩︎